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Abstract: To study the antiparasitic 8-nitroquinolin-2(1H)-one 
pharmacophore, a series of 31 derivatives was synthesized in 1-5 steps 
and evaluated in vitro against both Leishmania infantum and Trypanosoma 
brucei brucei. In parallel, the reduction potential of all molecules was 
measured by cyclic voltammetry. Structure-activity relationships first 
indicated that antileishmanial activity depends on an intramolecular 
hydrogen bond (described by X-ray diffraction) between the lactam 
function and the nitro group, which is responsible for an important shift 
of the redox potential (+0.3 V in comparison with 8-nitroquinoline). With 
the assistance of computational chemistry, a set of derivatives 
presenting a large range of redox potentials (from -1.1 to -0.45 V) was 
designed and provided a list of suitable molecules to be synthesized and 
tested. This approach highlighted that, in this series, only substrates 
with a redox potential above -0.6 V display activity toward L. infantum. 
Nevertheless, such relation between redox potentials and in vitro 
antiparasitic activities was not observed in T. b. brucei. Compound 22 is 
a new hit compound in the series, displaying both antileishmanial and 
antitrypanosomal activity along with a low cytotoxicity on the human 
HepG2 cell line. Compound 22 is selectively bioactivated by the type 1 
nitroreductases (NTR1) of L. donovani and T. brucei brucei. Moreover, 
despite being mutagenic in the Ames test, as most of nitroaromatic 
derivatives, compound 22 was not genotoxic in the comet assay. 
Preliminary in vitro pharmacokinetic parameters were finally determined 
and pointed out a good in vitro microsomal stability (half-life > 40 min) 
and a 92% binding to human albumin. 
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ABSTRACT 
To study the antiparasitic 8-nitroquinolin-2(1H)-one pharmacophore, a series of 31 derivatives was 
synthesized in 1-5 steps and evaluated in vitro against both Leishmania infantum and Trypanosoma 
brucei brucei. In parallel, the reduction potential of all molecules was measured by cyclic 
voltammetry. Structure-activity relationships first indicated that antileishmanial activity depends on an 
intramolecular hydrogen bond (described by X-ray diffraction) between the lactam function and the 
nitro group, which is responsible for an important shift of the redox potential (+0.3 V in comparison 
with 8-nitroquinoline). With the assistance of computational chemistry, a set of derivatives presenting 
a large range of redox potentials (from -1.1 to -0.45 V) was designed and provided a list of suitable 
molecules to be synthesized and tested. This approach highlighted that, in this series, only substrates 
with a redox potential above -0.6 V display activity toward L. infantum. Nevertheless, such relation 
between redox potentials and in vitro antiparasitic activities was not observed in T. b. brucei. 
Compound 22 is a new hit compound in the series, displaying both antileishmanial and 
antitrypanosomal activity along with a low cytotoxicity on the human HepG2 cell line. Compound 22 
is selectively bioactivated by the type 1 nitroreductases (NTR1) of L. donovani and T. brucei brucei. 
Moreover, despite being mutagenic in the Ames test, as most of nitroaromatic derivatives, compound 
22 was not genotoxic in the comet assay. Preliminary in vitro pharmacokinetic parameters were finally 
determined and pointed out a good in vitro microsomal stability (half-life > 40 min) and a 92% 
binding to human albumin. 
KEYWORDS 
Anti-kinetoplastids, Leishmania, Trypanosoma, 8-Nitroquinolin-2(1H)-one, Nitroreductases, 
Electrochemistry. 
HIGHLIGHTS 
8-nitroquinolin-2(1H)-one derivative 22 is bioactivated by L. donovani NTR1 
They display suitable redox potentials thanks to an intramolecular H-bond 
Introducing a bromine atom at position 3 leads to a new antikinetoplastid hit 
INTRODUCTION 
Kinetoplastids are protozoan parasites responsible for deadly mammalian infections; Leishmania spp 
and Trypanosoma spp being the two main genera encountered in human pathology. These parasites are 
transmitted to their mammalian hosts by the bite of specific insect vectors. Among the Leishmania 
genus, L. donovani and L. infantum are the two most important species responsible for visceral 
leishmaniasis (VL), the most severe and often lethal clinical form of the disease. Briefly, VL occurs in 
humans after the bite of a sandfly (Phlebotominae) which injects the metacyclic flagellated 
promastigote stage of the parasite into the skin. Parasites are then phagocytized by macrophages and 
other types of mononuclear phagocytic cells where they transform into the amastigote stage and 
multiply, bypassing the immune system of the host. Infected cells disseminate in many tissues and 
organs such as lymph nodes, liver, spleen and bone marrow, leading to death.
1
 In the Trypanosoma 
genus, in addition to T. cruzi species, causing Chagas disease in South and Central America, the T. 
brucei species (T. brucei gambiense or T. brucei rhodesiense) are responsible for Human African 
Trypanosomiasis (HAT), also called “sleeping sickness”. During HAT, the flagellated trypomastigote 
stage of the parasites penetrates into the blood stream via the bite of a “tsetse fly” and disseminates 
into the whole organism. In a first step of the disease, headaches, anemia, joint pain and various organ 
damage occur. Then, in a second step, the parasites invade the central nervous system, causing various 
neurological changes such as sleeping disorders (responsible for the name of the disease), abnormal 
tone and mobility, ataxia, psychiatric disorders, seizures, coma and finally, death.
2
  
It is important to note that all these kinetoplastid infections are lethal if untreated and that very few 
efficient, safe and affordable drugs are available on the market for the low-income infected patients 
living in developing countries, which makes these parasitic infections belong to the group of 
“Neglected Tropical Diseases”.3 Regarding recent epidemiologic data, the WHO indicates that more 
than 1 billion people are at risk of contracting VL and that 300.000 new cases occur every year, 
responsible for about 20.000 deaths.
4
 Concerning HAT, 61 million people would be at risk of 
contracting the disease, no clear data being available about HAT mortality.
5
 Approved drugs against 
VL are amphotericin B, miltefosine, antimony V derivatives and pentamidine. The liposomal form of 
amphotericin B, although being quite efficient, is also very expensive and requires parenteral 
administration, which makes it unsuitable for treating most of infected patients.
6
 Pentamidine and 
pentavalent antimony derivatives are toxic agents which use is limited by parasitic resistances and 
poor efficacy.
7
 Miltefosine (Figure 1) remains the only orally available drug, but it is a teratogenic 
molecule, preventing its use in women of child-bearing age.
6
 The context of anti-HAT drugs is quite 
similar with only one orally available drug.
8
 In addition to pentamidine, suramin is used in the 
treatment of the first stage of the disease, with nifurtimox in combination with eflornithine 
(NECT,Figure 1) for treatment of the second (cerebral) stage of HAT.
 
NECT has largely replaced the 
use of melarsoprol, a highly toxic arsenic-containing drug.
2
 
 
Figure 1: Structures of the antikinetoplastid drugs miltefosine and eflornithine, drug-candidate 
fexinidazole and antileishmanial hit 8-nitroquinolin-2(1H)-one 
Unfortunately, there are very few new chemical entities under clinical trial in 2018 against both VL 
and HAT.
8
 In this worrying context, there is a critical need to identify new active molecules and, as 
observed in the field of tuberculosis, various nitroheterocycles such as delamanid and fexinidazole are 
re-emerging as key anti-infective molecules.
9, 10
 Fexinidazole (Figure 1) is a 5-nitroimidazole 
derivative that was first evaluated against visceral leishmaniasis in a phase II clinical trial. Although 
not sufficiently efficient for use as a monotherapy for VL, fexinidazole has now demonstrated efficacy 
against early and late stages of HAT in a pivotal Phase III clinical trial.
11-12
 Fexinidazole is part of 
these nitroaromatic molecules which are selectively activated by parasitic nitroreductases (NTRs) to 
generate electrophilic cytotoxic metabolites.
13,14
 Unfortunately, no parasitic NTR X-ray structure is 
available and most classical rational medicinal chemistry approaches cannot be used for the design of 
new synthetic substrates of these key enzymes. In this context, our group initiated a research around a 
class of 8-nitroquinoline derivatives with antiparasitic potential
15
 and identified an antileishmanial 
pharmacophore in 2012, corresponding to the 8-nitroquinolin-2(1H)-one scaffold (Figure 1).
16
 Some 
more recent modulations of the position 4 of this pharmacophore failed to achieve more active 
derivatives.
17, 18
 Here, we present a comprehensive study of the structure-activity relationships of this 
pharmacophore, especially focusing on the modulation of the redox potentials. Thirty one 
pharmacophore derivatives, substituted at positions 3, 4, 5, 6 and 7, were synthesized and their in vitro 
cytotoxicity and activities against L. infantum (axenic amastigotes), and T. brucei brucei 
(trypomastigotes) were first determined. The original pharmacophore possessed poor antitrypanosomal 
activity, whereas a new derivative (compound 22) was identified, active against all tested 
kinetoplastids (L. donovani promastigotes, L donovani intramacrophage amastigotes, L. infantum 
axenic amastigotes and T. brucei brucei trypomastigotes). The antileishmanial mechanism of action of 
this new hit-compound will be discussed along with its mutagenicity and genotoxicity, a key aspect 
concerning nitroaromatic compounds. Finally, two preliminary in vitro pharmacokinetic properties 
were measured and appear favorable for further development of this anti-kinetoplastid pharmacophore. 
 
RESULTS AND DISCUSSION 
Chemistry 
Thirty one derivatives of the initial 8-nitroquinolin-2-(1H)-one pharmacophore, including 14 original 
ones, were prepared. As presented in Scheme 1, compounds 1-5 were obtained by classical nitration, 
cyclo-condensation or N-acetylation reactions. Nitration at position 8 of 2-chloro-4-methylquinoline 
afforded 6 whose chloroimine moiety reacted with perchloric acid to generate the corresponding 
lactam 7, according to a simple and efficient previously reported procedure.
19
 Bromination of 7 with 
N-bromosuccinimide led to the bromomethyl derivative 8 which was reacted with sodium hydroxide 
to generate hydroxymethyl derivative 9. From bromomethyl 8, by reacting with an amine, it was also 
possible to access to 10 and its deprotected counterpart 11. From 2,4-dibromoquinoline, by a 
sequential nitration/lactamisation procedure, 12 and 13 were obtained in good yields. 
 
Scheme 1: Synthetic routes for the preparation of compounds 1-13. (a) H2SO4, HNO3, rt, 1 h; (b) glyoxylic acid, 
EtOH, 80 °C, 6 h; (c) CH3COOH, Ac2O, 120 °C, 3 h; (d) H2SO4, HNO3, rt, 4 h; (e) CH3COOH, Ac2O, 120 °C, 
24 h; (f) H2SO4, HNO3, rt, 3 h; (g) CH3CN, HClO4, 100 °C, 24 h; (h) NBS, AIBN, CCl4, 80 °C, 24 h; (i) NaOH, 
H2O/THF, 50 °C, 24 h; (j) NH2(CH2CH2O)2CH2CH2NHBoc, THF, 50 °C, 24 h; (k) HCl (5N in isopropanol), rt, 
4 h; (l) H2SO4, HNO3, rt, 2 h; (m) CH3CN, HClO4, MW, 100 °C, 1 h. 
 
As presented in Scheme 2, the 2-chloroquinoline was the main substrate used in this work. It was first 
reacted with perchloric acid to generate lactam 14 which was either nitrated at position 6, to afford 
compound 15 or N-methylated with methyl iodide, to afford 16 in good yields. The nitration of 2-
chloroquinoline mainly leaded to the 2 position isomers 17 and 18 which were transformed into the 
corresponding lactams 19 and 20. Compound 20 was either O-methylated with methyl iodide, forming 
21, or selectively halogenated at position 3 by refluxing in HBr or HCl in the presence of sodium 
bromate or sodium chlorate, to generate derivatives 22 and 23. Note that this specific halogenation 
procedure (in situ Br2 or Cl2 formation and reaction in refluxing aqueous medium), reported by 
O’Brien and co-workers,20 is the only one allowing selective halogenation at position 3 among many 
others that were tested. The 3-brominated derivative 22 reacted with methyl iodide to form O-
methylated derivative 24 or was reduced into the amino-derivative 25 by using SnCl2. 
 
Scheme 2: Preparation of compounds 14-25 from 2-chloroquinoline. (a) CH3CN, HClO4, 100 °C, 72 h; (b) 
H2SO4, HNO3, rt, 1 h; (c) DMF, K2CO3, CH3I, 80 °C, 48 h; (d) H2SO4, HNO3, rt, 2 h; (e)  CH3CN, HClO4, 100 
°C, 72 h ; (f)  CH3CN, HClO4, 100 °C, 72 h; (g)  Ar., DMF, NaH, CH3I, rt, 24 h; (h) NaBrO3, HBr, 100 °C, 5 h; 
(i)  NaClO3, HCl, 100 °C, 45 min; (j)  Ar., DMF, NaH, CH3I, rt, 24 h; (k) EtOH, SnCl2, 80°C, 3 h. 
 
Finally, as presented in Scheme 3, we also used another synthetic pathway allowing the preparation of 
8-nitroquinolinone derivatives bearing substituents on the benzene moiety. This strategy was reported 
by Zaragoza and co-workers.
21
 First, commercial 3,3’-diethoxyethylpropionate was saponified into the 
corresponding carboxylic acid which was then reacted with SOCl2 to form the acyl chloride. This acyl 
chloride was then reacted with various ortho-nitroanilines, to give the corresponding N-acylated 
products which were not isolated. In a final step, cyclization was operated in 98% H2SO4, giving the 
expected products 26-31. The reaction yields are moderate when using 2-nitroanilines substituted at 
position 3 or 5 by electron donating groups but turn to be very low when using 2-nitroanilines 
substituted at position 4 by the same groups. 
 
Scheme 3: Preparation of compounds 26-31 from nitroanilines subtrates. (a) CH2Cl2, Pyridine, rt, 24 h; (b) 
H2SO4, rt, 3-4 h. 
 
 
  
Compound evaluation 
In vitro activity against L. infantum and T. brucei brucei: importance of the redox potential 
All synthesized molecules were screened in vitro toward both L. infantum axenic amastigotes and T. 
brucei brucei trypomastigotes and compared with commercial reference drugs (amphotericin B and 
miltefosine against L. infantum, suramin and eflornithine against T. brucei) along with drug-candidate 
fexinidazole (Table 1). To assess antiparasitic selectivity, the cytotoxicity of all compounds was also 
measured on the HepG2 human cell line, using doxorubicin as control. In parallel the LogP of all 
compounds were calculated and the reduction potentials were measured by cyclic voltammetry in 
DMSO. The redox potentials measured correspond to a one electron reduction/oxidation regarding the 
redox couple nitro group / anion radical. Only one new hit compound (22) was evaluated in greater 
depth, as the best compound in the series regarding both activity and selectivity. 
Globally, apart from molecule 24, all synthesized compounds were soluble in aqueous medium and 
could be evaluated in vitro. Out of the 31 tested compounds, none appeared cytotoxic on the HepG2 
cell line, nine were active toward L. infantum axenic amastigotes (7 µM ≤ IC50 ≤ 25 µM) and thirteen 
were active against T. brucei brucei trypomastigotes (2 µM ≤ IC50 ≤ 25 µM), molecule 24 being 
excluded from the analysis because of its lack of solubility. As a first approach, we wanted to see if 
there was a relationship between activity and lipophilicity. Computed LogP, ranging from 1.15 to 2.5 
did not show any correlation, active molecules presenting either low (compound 2) or high (compound 
22) LogP values.  
We then explored the structure-activity relationships (SARs) of the pharmacophore by focusing on the 
influence of the redox potentials toward the activity against L. infantum. Indeed, on the basis that this 
nitroaromatic pharmacophore could be the substrate of parasitic nitroreductases, it first appeared 
important to understand which chemical criteria would make this pharmacophore suitable for being 
efficiently reduced into cytotoxic metabolites. The basic redox potential value of 8-nitroquinoline 1 (-
0.84 V) and nitrobenzene (-0.85 V) are quite low and do not seem suitable for the catalytic capabilities 
of the parasitic nitroreductases (Figure 2). On the contrary, when the lactam function is combined with 
the presence of a nitro group at position 8 (initial hit), a significant increase in the value of the redox 
potential, up to -0.54 V, is observed and the molecule turns active. When keeping the lactam function 
while moving the nitro group at position 6 or 5 (compounds 15 and 19), redox potentials become 
lower and the IC50 values of the molecules increased, resulting in a loss of activity against L. infantum. 
The same effect is noted with inactive O-methylated analog (compound 21), which redox potential 
drastically fell to -0.93 V (Figure 2). Finally, adding an amide function in the ortho position of the 
nitrogroup (compounds 3 and 5) did not provide an optimal value of redox potential (-0.68 V and -
0.86 V, respectively) resulting in poor antileishmanial activity of the compounds. Thus the 8-
nitroquinolin-2-(1H)-one scaffold definitely appears to be the antileishmanial pharmacophore. 
Besides, as presented in the X-ray diffraction structures (Figure 3), this pharmacophore presents a 
noticeable intramolecular hydrogen bond between the lactam function and the nitro group at position 
8, responsible for a +0.3 V increase in redox potentials, allowing antileishmanial activity. 
Nevertheless, molecules 26 and 30, which present the same redox potential, do not have the same 
antileishmanial activity (26 being moderately active and 30 being inactive). By examining their LogP 
values (respectively 2.05 and 1.38) it could be hypothesized that antileishmanial activity depends on a 
compromise between redox potential values and lipophilicity. 
 
 
 
 
 
 
 
 
 Table 1: Reduction potentials, calculated LogP, anti-kinetoplastid activity and cytotoxicity of the 
synthesized nitroaromatic compounds 1-31. 
Molecule Structure 
E° 
(V/NHE)
a
 
LogP
b
 
L. infantum axenic 
amastigote  
IC50 (µM) 
T. brucei brucei 
trypomastigote  
IC50 (µM) 
HepG2 
Cytotoxicity 
CC50 (µM) 
Initial hit 
 
- 0.54 1.54 15.5 +/-0.5 23.4 +/-5.7 164 +/-28 
Nitro-
benzene (NB) 
 
- 0.85 1.91 > 100
d
 > 50
d
 > 100
d
 
1 
 
- 0.84 2.07 > 100
d
 17.9 +/-1.8 > 100
d
 
2 
 
- 0.46 1.2 11.0 +/-2.1 7.3 +/-0.8 125 +/-19 
3 
 
- 0.68 1.15 > 100
d
 > 50
d
 > 100
d
 
4 
 
- 1.1 1.89 > 100
d
 > 50
d
 > 100
d
 
5 
 
- 0.86
c
 1.31 > 100
d
 10.8 +/-1.4 > 100
d
 
7 
 
- 0.53 2.05 10.2 +/-1.0 20.9 +/-8.9 110 +/-9 
9 
 
- - 23.4 +/-4.8 38.3 +/-6.1 > 100
d
 
10 
 
- - > 100
d
 2.5 +/-1.8 > 100
d
 
11 
 
- - > 100
d
 7.6 +/-1.8 > 100
d
 
13 
 
- 0.51 1.86 20.3 +/-5.0 5.5 +/-1.3 60 +/-2 
14 
 
- 1.86
b
 - > 100
d
 > 50
d
 > 100
d
 
15 
 
- 0.82 1.54 > 100
d
 2.3 +/-0.6 > 100
d
 
16 
 
- - > 100
d
 > 50
d
 > 100
d
 
19 
 
- 0.67 1.54 > 100
d
 > 50
d
 > 100
d
 
21 
 
- 0.93 2.51 88.8 +/-13.0 28.5 +/-8.1 > 100
d
 
22 
 
- 0.45 2.36 7.1 +/-1.5 1.9 +/-0.4 92 +/-13 
23 
 
- 0.47 2.2 16.0 +/-0.9 1.2 +/-0.2 85 +/-4 
24 
 
- 0.86 - > 6.2
e
 0.4 +/-0.1 > 6.2
e
 
25 
 
- - > 50
d
 > 50
d
 > 100
d
 
26 
 
- 0.58 2.05 25.2 +/-3.7 29.1 +/-4.7 > 100
d
 
27 
 
- 0.56 2.05 23.0 +/-5.0 2.1 +/-0.8 > 100
d
 
28 
 
- 0.71 2.05 > 100
d
 > 50
d
 > 100
d
 
29 
 
- 0.65 1.38 > 100
d
 > 50
d
 > 100
d
 
30 
 
- 0.58 1.38 > 100
d
 > 50
d
 > 100
d
 
31 
 
- 0.75 1.38 > 100
d
 > 50
d
 > 100
d
 
Doxorubicin
f
 - - - - 0.2 +/-0.02 
Amphotericin B
g
 - - 0.06 +/-0.001 - 5.5 +/-0.25 
Miltefosine
g
 - - 0.8 +/-0.2 - 85 +/-8.8 
Fexinidazole
g,h
 - - 3.4 +/-0.8 0.4 +/-0.2 > 200
c
 
Suramin
h
 - - - 0.02 +/-0.009 > 100
c
 
Eflornithine
h
 - - - 15.8 +/-2.1 > 100
c
 
a Cyclic voltammetry conditions: DMSO/TBAPF6, SCE/GC, 1 electron reversible reduction, values are given in V versus NHE 
b Weighted logP were computed with Marvin® (ChemAxon) 
c Irreversible reduction 
d The IC50 or CC50 value was not reached at the highest tested concentration 
e The product could not be tested at higher concentrations due to a poor solubility in aqueous medium 
f Doxorubicin was used as a cytotoxic reference drug 
g Amphotericin B, Miltefosine and Fexinidazole were used as antileishmanial reference drugs 
h Fexinidazole, Suramin and Eflornithine were used as anti-Trypanosoma brucei reference drugs 
 
 
Figure 2: The 8-nitroquinolin-2(1H)-one pharmacophore presented a characteristic high redox 
potential value. 
 
 
 
Figure 3: X-ray structures of initial hit and new hit 22 presenting an intramolecular hydrogen bond 
between the lactam function and the nitro group (Initial hit: N-H distance = 0.89 Å, H-O distance = 
2.01 Å, N-H-O angle = 129°; Hit 22 : N-H distance = 0.84 Å, H-O distance = 2.01 Å, N-H-O angle = 
131°). 
Contrary to what was observed in Leishmania, the antitrypanosomal activity did not depend on the 
redox potential values in the studied series, active molecules presenting either low (compound 15) or 
high (compound 22) redox potential values. It could be hypothesized that the enzymatic capabilities of 
the T. brucei NTR may be compatible with a broader spectrum of redox potentials than the ones of L. 
donovani NTR. 
Optimization of redox potentials: computational and in vitro studies. 
From this point, we investigated the antileishmanial pharmacomodulation of 8-nitroquinolin-2(1H)-
one by introducing various substituents (or heteroatoms) at all positions of the scaffold and compared 
the effect of electron-donating and electron withdrawing groups, to gain access to new optimized 
derivatives. Our goal was to synthesize a series of derivatives presenting a large spectrum of redox 
potentials, not only to gain a better understanding of the electrochemical process, but also to define as 
precisely as possible the lowest redox potential value compatible with activity in the series. For that 
purpose instead of synthesizing molecules randomly, we used ab initio calculations to estimate the 
redox potential values of many hypothetical derivatives. Previous studies about the computation of 
reduction potentials of nitroaromatic derivatives showed that the results are very sensitive to the basis 
set applied. Diffuse s and p-type functions, combined with polarization functions were shown to be 
important for electron affinity calculations of nitrobenzenes
22,23
. Because accurate results were 
obtained with the Pople's 6-311++G basis set on several molecules for which computed potentials 
were compared to experimental ones, the 6-311++G(2d,2p) basis set was selected as a good 
compromise between accuracy and computational cost for reduction potential calculations. The hybrid 
M06-2x density functional was chosen for its accuracy to compute thermochemical parameters. The 
standard redox potentials were computed with the Faraday’s law (see equation (1) in the experimental 
section) from the free energy of the one-electron reduction. Figure 4 shows the correlation between the 
experimental and theoretical redox potentials. It can be seen that the slope of the correlation is close to 
1.00 and the correlation coefficient (r) is 0.97. Therefore, this model was very efficient for predicting 
the standard redox potentials and was used to select the most appropriate compounds to be synthesized 
and evaluated.  
 
 
Figure 4: Correlation between theoretical and experimental standard redox potential of nitroquinolines 
 
The studied series was completed with 11 derivatives of the pharmacophore presenting redox 
potentials ranging from -0.75 V to -0.45 V. Figure 5 shows that introducing a heteroatom at position 4 
of the scaffold (quinoxaline analog 2) or a halogen atom at position 3 (compounds 22 and 23) 
increased the redox potential values by about +0.1 V, the corresponding molecules being active 
against L. infantum. When modifying the pyridinone moiety by introducing a methyl group or a 
bromine atom at position 4 (compounds 7 and 13, respectively), the redox potential almost remained 
unchanged and the molecules were active. By substituting the benzene moiety with a methyl group at 
position 5 or 6 (compounds 26 and 27), the redox potentials decreased slightly (down to -0.58 V) and 
the molecules, were less efficient (IC50 ≈ 25 µM). Compounds bearing a methoxy group at positions 5, 
6 or 7 (compounds 29-31) or a methyl group at position 7 (compound 28) showed lower redox 
potentials, varying from -0.58 V to -0.75 V, and were totally inactive (IC50 > 100 µM). Thus, in this 
series, it can be noted that the optimal redox potential value to target in order to obtain antileishmanial 
activity is -0.5 V and that molecules whose redox potential is positioned below -0.6 V lost all activity. 
Figure 5: Modulation of the redox potential of the 8-nitroquinolin-2[1H]-one pharmacophore. 
 
Mode of action studies, genotoxicity evaluation and preliminary pharmacokinetic properties of 
22 
Among all synthesized compounds, derivative 22 was highlighted as a new hit (Table1). It is not only 
active against L. infantum (IC50 = 7.1 µM), but also against T. brucei brucei (IC50 = 1.9 µM), which 
was not the case of the initial hit, displaying modest activity (IC50 = 23.4 µM) toward the latter 
parasite. For comparison with the anti-leishmanial reference drugs, hit compound 22 appears much 
less active than amphotericin B and about 10 times less active than miltefosine (with equivalent 
cytotoxicity). Regarding anti-HAT drugs, hit compound 22 appears much less active than suramin, but 
more active than eflornithine. It is also important to compare hit molecule 22 with drug candidate 
fexinidazole, as they both belong to the nitroaromatic family: 22 is about 2 times more cytotoxic and, 
depending on the parasite, between 2 to 5 times less active than this drug candidate, which remains 
interesting for a hit-compound. It was then necessary to evaluate the in vitro activity of 22 against the 
amastigote stage of Leishmania in an intramacrophage model, closer to the in vivo situation. As 
presented in Table 2, the test was done on L. donovani, the other species responsible for VL. Hit 
molecule 22, displays a low cytotoxicity on the THP1 macrophage cell line (CC50 = 72 µM) and is 
about 3 times less active (IC50 = 18 µM) on this intramacrophage amastigote in vitro model than 
miltefosine (IC50 = 5.4 µM). Fexinidazole is not active on the intramacrophage amastigote stage (IC50 
> 50 µM) as it first needs to be metabolized into a sulfone derivative.
24
 Finally, as expected, 
compound 14 (non nitrated) and 25 (8-amino derivative), negative controls deriving from hit 22, did 
not display any antiparasitic activity. 
In order to assess whether this compound series was a substrate of parasitic NTRs, the hit compound 
22 was assayed against a wild type strain of L. donovani promastigotes and two strains overexpressing 
NTR1
25
 and NTR2
26
, respectively (Table 2). Compound 22 was ten times more effective against the 
strain overexpressing NTR1 (IC50 = 0.47 µM) vs WT and NTR2 strains, indicating that it is selectively 
bioactivated by NTR1 of L. donovani. Interestingly, this is the same type 1 nitroreductase that 
bioactivates fexinidazole and its metabolites.
25
 Following the same approach in T. brucei brucei, it was 
also demonstrated that type 1 NTR, the unique NTR enzyme expressed in this parasite, was 
responsible for the bioactivation of 22 (Table 2). 
Nitroaromatic drugs are often suspected to be mutagenic or genotoxic, which has considerably limited 
the development of such derivatives in the past decades.
27 
The most famous in vitro test used for 
evaluating mutagenicity is the Ames test, using Salmonella typhimurium strains. Nevertheless, 
considering that Salmonella bacteria possess nitroreductases,
28
 the Ames test is usually positive when 
evaluating nitroaromatics, with no real predicting character for humans, considering that there are no 
NTRs in mammalian cells and that most of nitroaromatic derivatives only exert a genotoxic character 
after being bioactivated into reduced metabolites.
27
 For that reason, it is nowadays accepted that the 
comet assay or the micronucleus assay are better in vitro tools for evaluating the potential genotoxicity 
of nitroaromatics.
27
 Indeed, metronidazole, one of the most famous anti-infective nitroheterocycles on 
the market, is mutagenic in the Ames test, but not genotoxic in the comet assay
29
 and fexinidazole is 
not genotoxic in the micronucleus assay despite being mutagenic in the Ames test.
24
 Regarding 
compound 22, the Ames test (in metabolizing conditions) and the comet assay were done in parallel 
and revealed that, although being mutagenic in the Ames test (Table 3) at 0.25 or 2.5 mM, compound 
22 was not genotoxic in the comet assay after 2 or 72 h of exposure, at 1, 10, 20 or 40 µM (Figure 6), 
concentrations chosen from the HepG2 CC10% (40 µM). This lack of genotoxicity is a key point when 
thinking about further development of this pharmacophore. Finally, preliminary in vitro 
pharmacokinetic evaluations were done with compound 22 (Table 2). It presented a very good 
microsomal stability (T1/2 > 40 min) and had a strong, but not extreme binding to human albumin 
(92%), in relation with the relatively high value of its calculated logP (= 2.36).  
 
Table 2: Complementary in vitro biological evaluations done on hit compound 22 
In vitro studies 
 
Cytotoxicity: CC50 THP1 (µM)
a
 72 +/-6 
IC50 L. donovani intramacrophagic amastigotes (µM)
b
 18 +/-2 
IC50 L. donovani promastigotes  
wild type strain (µM) 
5.9 +/-0.12 
IC50 L. donovani promastigotes  
NTR1 over-expressing strain (µM) 
0.47 +/-0.02 
IC50 L. donovani promastigotes  
NTR2 over-expressing strain (µM) 
4.6 +/-0.12 
IC50 T. b. brucei  trypomastigotes  
wild type strain (µM) 
17.7 +/-1.0 
IC50 T. b. brucei  trypomastigotes  
NTR1 over-expressing strain (µM) 
3.9 +/-0.1 
Microsomal stability: T1/2 (min) > 40 
Binding % to human albumin 92 
aReference compounds: Amphotericin B CC50 = 3.6 +/-0.7 µM; Miltefosine CC50 > 40 µM; Fexinidazole CC50 > 62.5 µM 
bReference compounds: Amphotericin B IC50 = 0.4 µM; Miltefosine IC50 = 5.4 µM; Fexinidazole IC50 > 50 µM 
  
 
 
Table 3: Ames test results for hit compound 22 
 
 
 
 0.25 mM 2.5 mM 
TA97a + S9 mix Positive Positive 
TA98 + S9 mix Positive Positive 
TA100 + S9 mix Positive Positive 
TA102 + S9 mix Negative Positive 
                                      benzo[a]pyrene was used as a positive control  
 
 
 
Figure 6: results of the comet assay for hit compound 22.  
Positive control = MMS = 1 mM methylmethanesulfonate 
 
  
 
CONCLUSION 
Starting from the previously identified 8-nitroquinolin-2(1H)-one antileishmanial pharmacophore, an 
electrochemistry-guided SAR study revealed that an intramolecular hydrogen bond between the lactam 
ring and the nitro group is responsible for a +0.3 V increase in the redox potential value (compared 
with 8-nitroquinoline) resulting in improved antileishmanial activity. A computational model allowed 
the prediction of the redox potential values of any derivative belonging to this series, and we 
synthesized a set of derivatives presenting a large range of redox potential values. Then, it was 
highlighted that, to be active, molecules belonging to this series must display a redox potential value 
of about -0.5 V and that molecules with a redox potential below -0.6 V were inactive. By introducing 
electron-withdrawing groups on the pyridone moiety of the scaffold, a new original hit compound was 
found: 22. Presenting a low cytotoxicity on the human HepG2 cell line (CC50 = 92 µM), it displays 
activity toward L. infantum axenic amastigotes (IC50 = 7.1 µM), L. donovani promastigotes (IC50 = 5.9 
µM) and L. donovani intramacrophagic amastigotes (IC50 = 18 µM), but also toward T. brucei brucei 
(IC50 = 1.9 µM). Moreover, we demonstrated that 22 was not genotoxic in the comet assay and that it 
was selectively bioactivated by the mitochondrial NTR1 of L. donovani and T. brucei brucei. This 
whole study, completed with two encouraging preliminary in vitro pharmacokinetic parameters (good 
microsomal stability and 92% binding to human albumin) now opens the way to the rational 
conception, guided with E° values, of new efficient, selective and safe NTR1 bioactivated 8-
nitroquinolin-2(1H)-ones against VL and HAT. 
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EXPERIMENTAL SECTION 
Chemistry 
All reagents and solvents were obtained from commercial sources (Fluorochem®, Sigma-Aldrich® or 
Alfa Aesar®) and used as received. The progress of the reactions was monitored by pre-coated thin 
layer chromatography (TLC) sheets ALUGRAM
®
 SIL G/UV254 from Macherey-Nagel and were 
visualized by ultraviolet light at 254 nm. The NMR 
1
H and 
13
C spectra were recorded on a Bruker 
UltraShield 300 MHz, a Bruker IconNMR 400 MHz, or a Bruker Avance NEO 600 MHz instrument, at 
the Laboratoire de Chimie de Coordination and data are presented as follows: chemical shifts in parts 
per million (δ) using tetramethylsilane (TMS) as reference, coupling constant in Hertz (Hz), 
multiplicity by abbreviations : (s) singlet, (d) doublet, (t) triplet, (q) quartet, (dd) doublets of doublets, 
(m) multiplet and (br s) broad singlet. Melting points are uncorrected and were measured on a Stuart 
Melting Point SMP3 instrument. HRMS measurements were done on a GCT Premier Spectrometer (DCI, 
CH4, HRMS) or Xevo G2 QTOF (Waters, ESI+, HRMS) instrument at the Université Paul Sabatier, 
Toulouse. Microwave reactions were realized in a CEM Discover
®
 microwave reactor. All products were 
purified by chromatography columns and then recrystallized. Purity of the products was determined by 
1
H 
NMR. 
 
General procedure for the preparation of 8-nitroquinoline 1
30
, 7-amino-8-nitroquinoline 4
31
, 2-chloro-
4-methyl-8-nitroquinoline 6
32
, 2,4-dibromo-8-nitroquinoline 12
17
, 6-nitroquinolin-2(1H)-one 15
16
, 2-
chloro-5-nitroquinoline 17
16 
and 2-chloro-8-nitroquinoline 18
16
: 
H2SO4 (98%) was added onto 1 equiv. of the quinoline derivatives, cooled with an ice bath. 5 equiv. of 
65% HNO3 were then added dropwise at 0°C and the reaction mixture was stirred at rt for 1-4 h. The 
reaction mixture was successively poured into ice, neutralized with NaOH and extracted three times 
with dichloromethane. The organic layer was washed with water, dried over anhydrous Na2SO4 and 
evaporated in vacuo. The crude residue was purified by chromatography on silica gel using adapted 
eluent and recrystallized if necessary to give compounds 1, 4, 6, 12, 15, 17 and 18. 
 
8-nitroquinoline 1 (C9H6N2O2) was purified by chromatography on silica gel using dichloromethane as 
an eluent, separated from its 5-nitro isomer and isolated to yield a pale yellow solid (35%, 2.7 mmol, 
470 mg), mp 90 °C (Lit: 90 °C), 
1
H NMR (400 MHz, CDCl3) : 7.53-7.66 (m, 2 H), 8.04 (d, J = 8.0 
Hz, 2 H), 8.27 (dd, J = 1.6 and 8.4 Hz, 1 H, H7), 9.70 (dd, J = 1.7 and 4.2 Hz, 1 H, H2). 
13
C NMR 
(100 MHz, CDCl3) : 122.8 (CH), 123.8 (CH), 125.3 (CH), 129.0 (C), 132.0 (CH), 136.1 (CH), 139.5 
(C), 148.2 (C), 152.6 (CH). 
7-amino-8-nitroquinoline 4 (C9H7N3O2) was purified by chromatography on silica gel using 
dichloromethane/ethyl acetate (80/20) as an eluent and isolated to yield an orange solid (46%, 0.16 
mmol, 30 mg), mp 193 °C (Lit: 194 °C), 
1
H NMR (400 MHz, CDCl3) : 5.61 (br s, 2 H, NH2) ; 7.00 (d, 
J=9.0 Hz, 1 H, H6), 7.28 (dd, 1 H, J=4.4 and 8.1 Hz, H3), 7.69 (d, J= 9.0 Hz, 1H, H5),  8.00 (dd, 1 H, 
J=1.8 and 8.1 Hz, H4), 8.92 (dd, 1 H, J=1.8 and 4.4 Hz, H2). 13C NMR (100 MHz, Acetone d6): 118.90 
(CH), 119.8 (CH), 120.9 (C), 131.8 (CH), 135.7 (CH), 139.7 (C), 142.8 (C), 143.1 (C), 151.2 (CH).  
2-chloro-4-methyl-8-nitroquinoline 6 (C10H7ClN2O2) was purified by chromatography on silica gel 
using cyclohexane/acetone (70/30) as an eluent, separated from its 6-nitro isomer, isolated and 
recrystallized in isopropanol to yield a white solid in (53%, 14.8 mmol, 3.3 g), mp 143 °C (Lit: 142-
143 °C), 
1
H NMR (400 MHz, CDCl3) : 2.74 (d, J=1.0 Hz, 3 H, CH3), 7.35 (d, J=1.0 Hz, 1 H, H3), 
7.62-7.66 (m, 1 H, H6), 8.00 (dd, J= 7.6 and 1.3 Hz, 1 H, H5), 8.18 (dd, J= 8.4 and 1.3 Hz, 1 H, 
H7). 
13
C NMR (150 MHz, CDCl3) : 18.9 (CH3), 124.2 (CH), 124.5 (CH), 125.4 (CH), 127.8 (CH), 
127.9 (C), 138.9 (C), 147.8 (C), 147.9 (C), 153.2 (C). 
2,4-dibromo-8-nitroquinoline 12 (C9H4Br2N2O2) was purified by chromatography on silica gel using 
cyclohexane/acetone (9/1) as an eluent and isolated to yield a white solid (56%, 6 mmol, 2 g), mp 129 
°C (Lit: 129 °C), 
1
H NMR (400 MHz, CDCl3) : 7.72-7.76 (m, 1 H, H6), 8.00 (s, 1 H, H3), 8.08 (dd, 
J= 7.6 et 1.4 Hz, 1 H, H5), 8.39 (dd, J= 8.5 et 1.4 Hz 1 H, H7). 
13
C NMR (100 MHz, DMSO) : 125.3 
(CH), 126.9 (CH), 127.5 (C), 130.9 (CH), 131.0 (CH), 135.0 (C), 139.7 (C), 143.6 (C), 147.5 (C).  
6-nitroquinolin-2(1H)-one 15 (C9H6N2O3) was recrystallized in isopropanol to yield a yellow solid 
(91%, 6.3 mmol, 1.2 g), mp 279 °C (Lit: 279 °C), 
1
H NMR (300 MHz, DMSO d6) : 6.68 (d, J= 9.8 
Hz, 1 H, H3), 7.43 (d, J= 9.0 Hz, 1 H, H8), 8.12 (d, J= 9.8 Hz, 1 H, H4), 8.33 (dd, J= 2.6 and 9.0 Hz, 1 
H, H7), 8.70 (d, J= 2.6 Hz, 1 H, H5), 12,3 (br s, 1 H, NH). 
13
C NMR (75 MHz, DMSO d6) : 116.3 
(CH), 118.7 (C), 124.0 (CH), 124.5 (CH), 125.3 (CH), 140.3 (CH), 141.7 (C), 143.5 (C), 162.1 (C). 
2-chloro-5-nitroquinoline 17 (C9H5ClN2O2) was purified by chromatography on silica gel using 
cyclohexane/acetone (8/2) as an eluent, isolated and recrystallized in isopropanol to  yield a yellow 
solid (14% , 4.3 mmol, 0.9 g), mp 134 °C (Lit: 133-134 °C), 
1
H NMR (300 MHz, CDCl3) : 7.63 (d, 
J=9,1 Hz, 1 H, H4), 7.82-7.87 (m, 1 H, H7), 8.34 (dd, J= 8,6 and 0,7 Hz, 1 H, H8), 8.40 (dd, J= 7.6 
and 1.2 Hz, 1 H, H6), 8.99 (d, J=9.2 Hz, 1 H, H3). 
13
C NMR (100 MHz, CDCl3) : 120.1 (C), 125.0 
(CH), 125.6 (CH), 129.0 (CH), 135.1 (CH), 135.7 (CH), 145.6 (C), 148.2 (C), 152.6 (C). 
2-chloro-8-nitroquinoline 18 (C9H5ClN2O2) was purified by chromatography on silica gel using 
cyclohexane/acetone (8/2) as an eluent, isolated and recrystallized in isopropanol to  yield a yellow 
solid (50%, 15.3 mmol, 3.2 g), mp 152 °C (Lit: 152 °C), 
1
H NMR (400 MHz, CDCl3) : 7.56 (d, J=8.7 
Hz, 1 H, H4), 7.65-7.69 (m, 1 H, H6),  8.07 (dd, J= 8.3 and 1.4 Hz, 1 H, H5), 8.11 (dd, J= 7.6 and 1.4 
Hz, 1 H, H7), 8.23 (d, J=8.7 Hz, 1 H, H3). 
13
C NMR (150 MHz, CDCl3) : 124.6 (CH), 124.9 (CH), 
125.8 (CH), 127.6 (C), 131.8 (CH), 138.6 (CH), 139.0 (C), 147.1 (C), 153.6 (C). 
 
 
 
Preparation of 8-nitroquinoxalin-2(1H)-one 2
 
Ethanol (25 mL) was added onto 1 g of 3-nitro-1,2-phenylenediamine (6.53 mmol, 1 equiv.). 0.6 g of 
glyoxylic acid monohydrate (6.53 mmol, 1 equiv.) was then added at rt and the reaction mixture was 
stirred at 80°C for 6 h. The reaction mixture was poured into water and extracted three times with 
dichloromethane. The organic layer was washed with water, dried over anhydrous MgSO4 and 
evaporated in vacuo. The crude residue was purified by chromatography on silica gel using 
dichloromethane/diethyl ether (80/20) as an eluent. 8-nitroquinoxalin-2(1H)-one 2 was isolated and 
recrystallized in acetonitrile to yield an orange solid (46%, 2.98 mmol, 570 mg).  
Compound 2 (C8H5N3O3): mp 162 °C, 
1
H NMR (400 MHz, CDCl3) : 7.45-7.50 (m, 1 H, H6), 8.25 
(dd, J=1.5 and 8.2 Hz, 1 H, H5), 8.39 (d, J=2.2 Hz, 1 H, H3), 8.55 (dd, J=1.5 and 8.2 Hz, 1 H, H7), 
11.37 (br s, 1 H, NH). 
13
C NMR (100 MHz, CDCl3)  122.6 (CH), 127.8 (C), 128.0 (CH), 133.1 (C), 
133.8 (C), 137.4 (CH), 152.6 (CH), 153.6 (C). HRMS (DCI CH4) calcd for C8H6N3O3 [M+H]
+
 
192.0409, found 192.0412. 
 
Preparation of N-(2-Nitrophenyl)-acetamide 3
33 
Acetic acid (25 mL) was added onto 525 mg of 2-nitroaniline (3.8 mmol, 1 equiv.). The reaction 
mixture was then stirred at 120°C and 720 µL of acetic anhydride (7.6 mmol, 2 equiv.) were added 
dropwise. After 3 h under reflux, the reaction mixture was poured into ice, neutralized with Na2CO3 
and extracted three times with dichloromethane. The organic layer was washed with water, dried over 
anhydrous Na2SO4 and evaporated in vacuo. N-(2-Nitrophenyl)-acetamide 3 was isolated and 
recrystallized in acetonitrile to yield a yellow solid (87%, 3.3 mmol, 604 mg).  
Compound 3 (C8H8N2O3): mp 93 °C (Lit: 92-94 °C), 
1
H NMR (400 MHz, CDCl3) : 2.29 (s, 3 H, 
CH3), 7.16-7.20 (m, 1 H, H4), 7.63-7.67 (m, 1 H, H5), 8.21 (dd, J= 8.5 and 1.3 Hz, 1 H, H6), 8,77 (dd, 
J= 8.6 and 1.3 Hz, 1 H, H3), 10.33 (br s, 1H, NH). 13C NMR (100 MHz, CDCl3): 25.60 (CH3), 122.2 
(CH), 123.2 (CH), 125.7 (CH), 134.8 (C), 135.9 (CH), 136.3 (C), 169.0 (C).  
 
 
Preparation of 7-acetylamino-8-nitroquinoline 5
 
Glacial acetic acid (20 mL) was added onto 60 mg of 7-amino-8-nitroquinoline (0.32 mmol, 1 equiv.). 
The reaction mixture was then stirred at 120°C and 180 µL of acetic anhydride (1.6 mmol, 6 equiv.) 
were added dropwise. After 24 h under reflux, the reaction mixture was poured into ice, neutralized 
with K2CO3 and extracted three times with dichloromethane. The organic layer was washed with 
water, dried over anhydrous MgSO4 and evaporated in vacuo. The crude residue was purified by 
chromatography on silica gel using dichloromethane/ethyl acetate (90/10) as an eluent. 7-acetylamino-
8-nitroquinoline 5 was isolated and recrystallized in isopropanol to yield a yellow solid (53%, 0.17 
mmol, 39 mg). 
Compound 5 (C11H9N3O2): mp 189 °C, 
1
H NMR (300 MHz, CDCl3) : 2.28 (s, 3 H, CH3), 7.49 (dd, 
J=4.3 et 8.3 Hz, 1 H, H3), 7.96 (d, 1H, J= 9.2 Hz, H 6), 8.19 (dd, J=1.7 et 8.3 Hz, 1 H, H4), 8.35 (br s, 
1 H, NH), 8.54 (d, J=9.2 Hz, 1 H, H5), 8.99 (dd, J=1.7 et 4.3 Hz, 1 H, H2). 
13
C NMR (150 MHz, 
CDCl3) : 25.0 (CH3), 121.7 (CH), 121.9 (CH), 125.2 (C), 127.8 (C), 131.4 (CH), 131.8 (C), 135.8 
(CH), 140.3 (C), 152.6 (CH), 168.7 (C). HRMS (DCI CH4) calcd for C11H10N3O2 [M+H]
+
 232.0722, 
found 232.0719. 
 
General procedure for the preparation of 4-methyl-8-nitroquinolin-2(1H)-one 7
34
, quinolin-2(1H)-one 
14
35
, 5-nitroquinolin-2(1H)-one 19
16
 and 8-nitroquinolin-2(1H)-one 20
16
.  
Acetonitrile (25 mL) and 70 % perchloric acid solution (25 mL) were added onto 1 equiv. of the 
quinoline derivatives. The reaction mixture was stirred at 100°C overnight. The reaction mixture was 
then poured into ice, neutralized with KOH and extracted twice with dichloromethane. The organic 
layer was washed with water, dried over anhydrous MgSO4 and evaporated in vacuo. The crude 
residues were purified by chromatography on silica gel using adapted eluent and recrystallized if 
necessary to give compounds 7, 14, 19, 20. 
4-methyl-8-nitroquinolin-2(1H)-one 7 (C10H8N2O3) was isolated and recrystallized in acetonitrile to 
yield a yellow solid (92%, 11 mmol, 2.2 g), mp 203 °C (Lit: 196 °C), 
1
H NMR (400 MHz, DMSO) : 
3.33 (s, 3 H, CH3), 6.63 (s, 1 H, H3), 7.39-7.44 (m, 1 H, H6), 8.19 (dd, J= 8.0 and 1.3 Hz, 1H, H5), 
8.42 (dd, J= 8.4 and 1.6 Hz, 1 H, H7), 10.98 (br s, 1 H, NH). 
13
C NMR (DMSO, 100 MHz) : 19.6 
(CH3), 121.6 (CH), 122.0 (CH), 122.6 (C), 127.9 (CH), 133.1 (CH), 133.6 (C) 134.6 (C), 148.9 (C), 
161.0 (C). 
quinolin-2(1H)-one 14 (C9H7NO) was purified by chromatography on silica gel using 
dichloromethane/ethyl acetate (8/2) as an eluent and isolated to yield a white solid (74%, 22.7 mmol, 
3.3 g), mp 198 °C (Lit: 193 °C), 
1
H NMR (400 MHz, CDCl3) : 6.72 (d, J= 9.5 Hz, 1 H, H3), 7.20-
7.25 (m, 1 H, H6), 7.40-7,42 (m, 1 H, H5), 7.50-7.54 (m, 1 H, H7), 7.56-7.58 (m, 1 H, H8), 7.82 (d, J= 
9.5 Hz,1 H, H4), 11.97 (br s, 1 H, NH). 
13
C NMR (100 MHz, CDCl3) : 116.3 (CH), 119.9 (C), 121.3 
(CH), 122.7 (CH), 127.7 (CH), 130.7 (CH), 138.5 (C), 141.1 (CH), 164.7 (C). 
5-nitroquinolin-2(1H)-one 19 (C9H6N2O3) was isolated and recrystallized in acetonitrile to yield a 
yellow solid (92%, 2.2 mmol, 418 mg), mp 302 °C (Lit: 302 °C),
 1
H NMR (400 MHz, DMSO d6) : 
6.76 (d, J=10.0 Hz, 1 H, H3), 7.65-7.73 (m, 2 H, H7 H8), 7.88 (dd, J= 7.7 and 1.3 Hz, 1 H, H6), 8.25 
(d, J= 10.0 Hz, 1 H, H4), 12.3 (br s, 1 H, NH). 
13
C NMR (100 MHz, DMSO d6) : 111.9 (C), 118.9 
(CH), 121.5 (CH), 125.8 (CH), 130.6 (CH), 134.7 (CH), 140.7 (C), 146.7 (C), 161.3 (C). 
8-nitroquinolin-2(1H)-one 20 (C9H6N2O3) was isolated and recrystallized in isopropanol to yield a 
yellow solid (96%, 10.6 mmol, 2.02 g), mp 163 °C (Lit: 163 °C), 
1
H NMR (400 MHz, CDCl3) : 6.79 
(dd, J= 9.7 and 2.0 Hz, 1H, H3), 7.32-7.36 (m, 1 H, H6), 7.82 (d, J= 9.7 and 1.4 Hz, 1 H, H4), 7.91 
(dd, J= 7.6 Hz, 1 H, H5), 8.53 (dd, J= 8.4 and 1.4 Hz, 1 H, H7),  11.3 (br s, 1H, NH). 
13
C NMR (100 
MHz, DMSO d6) : 121.4 (CH), 122.1 (C), 123.8 (CH), 127.9 (CH), 133.1 (C), 133.9 (C), 135.6 
(CH), 139.9 (CH), 161.6 (C). 
 
Preparation of 4-bromomethyl-8-nitroquinolin-2(1H)-one 8
  
Carbon tetrachloride (15 mL) was added onto 400 mg of 4-methyl-8-nitroquinolin-2(1H)-one (1.9 
mmol, 1 equiv.) and 1.7 g of N-bromosuccinimide (9.7 mmol, 5 equiv.). The reaction mixture was 
heated at 80°C. Thent 31 mg of AIBN (0.24 mmol, 0.1 equiv.) were added, and stirred overnight. The 
reaction mixture was poured into water, extracted twice with dichloromethane and once with ethyl 
acetate. The combined organic layers were washed with water, dried over anhydrous MgSO4 and 
evaporated in vacuo. The crude residue was purified by chromatography on silica gel using ethyl 
acetate as an eluent. 4-bromomethyl-8-nitroquinolin-2(1H)-one 8 was isolated to yield a yellow solid 
(21%, 0.42 mmol, 120 mg).  
Compound 8 (C10H7BrN2O3): mp 161 °C, 
1
H NMR (400 MHz, CDCl3) : 4.60 (s, 2 H, CH2), 6.87 (d, 
J=2.0 Hz, 1 H, H3), 7.40-7.44 (m, 1 H, H6), 8.18 (dd, J= 1.3 and 8.8 Hz, 1 H, H5), 8.57 (dd, J= 1.3 
and 8.3 Hz, 1 H, H7), 11.44 (br s, 1 H, NH). 
13
C NMR (100 MHz, CDCl3,) : 27.9 (CH2), 120.2 (C), 
121.3 (CH), 123.7 (CH), 128.4 (CH), 132.4 (CH), 133.6 (C), 134.4 (C), 146.1 (C), 160.7 (C). HRMS 
(DCI CH4) calcd for C10H8BrN2O3 [M+H]
+
 282.9718, found 282.9723. 
 
Preparation of 4-hydroxymethyl-8-nitroquinolin-2(1H)-one 9
 
Fifty millilitres of a mixture H2O/THF (1/1) were added onto 150 mg of 4-bromomethyl-8-
nitroquinolin-2(1H)-one (0.53 mmol, 1 equiv). 106 mg of NaOH (2.6 mmol, 5 equiv.) were added and 
the reaction mixture was stirred at 50°C for 24 h. The reaction mixture was then poured into water, 
extracted twice with dichloromethane and twice with ethyl acetate. The combined organic layers were 
washed with water, dried over anhydrous MgSO4 and evaporated in vacuo. The crude residue was 
purified by chromatography on silica gel using ethyl acetate as an eluent. 4-hydroxymethyl-8-
nitroquinolin-2(1H)-one 9 was isolated to yield a yellow solid (43%, 0.23 mmol, 50 mg).  
Compound 9 (C10H8N2O4): mp 211 °C, 
1
H NMR (300 MHz, DMSO) : 4.80 (d, J=5.5 Hz, 2 H, CH2), 
5.67 (t, J=5.5 Hz, 1 H, OH), 6.73 (s, 1 H, H3), 7.37-7.42 (m, 1 H, H6), 8,13 (d, J= 7.9 Hz, 1 H, H5), 
8.42 (d, J= 8.3 Hz, 1 H, H7), 11,01 (br s, 1H, NH). 
13
C NMR (150 MHz, DMSO) : 39.5 (CH2), 122.0 
(CH), 122.1 (C), 123.0 (CH), 128.2 (CH), 133.3 (CH), 133.8 (CH), 136.5 (C), 141.3 (C), 161.6 (C). 
HRMS (DCI CH4) calcd for C10H9N2O4 [M+H]
+
 221.0562, found 221.0558. 
 
Preparation of 4-{[2-(N-boc-2-aminoethoxy)ethoxy]ethyl}aminomethyl-8-nitroquinolin-2(1H)-one 10
 
THF (50 mL) was added onto 500 mg of 4-bromomethyl-8-nitroquinolin-2(1H)-one (1.8 mmol, 1 
equiv.) and 1.3 g of N-Boc-2,2′-(ethylenedioxy)-diethylamine (5.3 mmol, 3 equiv.). Triethylamine 
(375 µL, 2.7 mmol, 1.5 equiv.) were then added and the reaction mixture was stirred at 50°C 
overnight. The reaction mixture was evaporated in vacuo. The crude product was then resolubilized in 
ethyl acetate, washed three times with water, dried over anhydrous MgSO4 and evaporated in vacuo. 
The crude residue was purified by chromatography on silica gel using diethyl ether/methanol/ 20% 
aqueous ammonia solution (8.9/1/0.1) as an eluent. 4-{[2-(N-boc-2-
aminoethoxy)ethoxy]ethyl}aminomethyl-8-nitroquinolin-2(1H)-one 10 was isolated to yield an orange 
oil (84%, 1.5 mmol, 680 mg).  
Compound 10 (C21H30N4O7): 
1
H NMR (600 MHz, DMSO) : 1.36 (s, 9H, tBu), 2.5 (s, 1 H, NH amine), 
2.75-2.77 (m, 2 H, CH2 3’), 3.03-3.06 (m, 2 H, CH2 10’), 3.36-3.39 (m, 2 H, CH2 4’), 3.51-3.54 (m, 6 H, 
3xCH2 6’ 7’ 9’), 4.02 (s, 2 H, CH2 1’), 6.73 (br s, 1 H, NH carbamate), 6.76 (s, 1 H, H3), 7.38-7.42 (m, 1 
H, H6), 8.31 (dd, J= 8.1 and 1.3 Hz, 1H, H5), 8.42 (dd, J= 8.1 and 1.3 Hz, 1 H, H7), 11.03 (br s, 1 H, 
NH).  
13
C NMR (150 MHz, DMSO) : 28.7 (3 CH3, tBu), 40.1 (CH2), 48.7 (CH2), 49.9 (CH2), 69.6 (CH2), 
70.0 (CH2), 70.1 (CH2), 70.5 (CH2), 78.0 (C), 120.5 (CH), 121.4 (C), 121.6 (CH), 127.8 (CH), 132.9 
(CH), 133.6 (C), 134.5 (C), 150.6 (C), 156.0 (C), 161.1 (C). HRMS (ESI) calcd for C21H31N4O7 
[M+H]
+
 450.2114, found 450.2118. 
 
Preparation of 4-{[2-(2-aminoethoxy)ethoxy]ethyl}aminomethyl-8-nitroquinolin-2(1H)-one 11
 
Hydrochloric acid (15 mL of 5 N HCL in isopropanol) was added onto 600 mg of 4-{[2-(N-boc-2-
aminoethoxy)ethoxy]ethyl}aminomethyl-8-nitroquinolin-2(1H)-one (1.33 mmol, 1 equiv.) and the 
reaction mixture was then stirred at rt for 4 h. The reaction mixture was successively poured into 
water, neutralized with K2CO3 and extracted several times with dichloromethane. The organic layer 
was dried over anhydrous Na2SO4 and evaporated in vacuo. 4-{[2-(2-
aminoethoxy)ethoxy]ethyl}aminomethyl-8-nitroquinolin-2(1H)-one 11 was isolated to yield an oil in 
(43%, 0.57 mmol, 200 mg). 
Compound 11 (C16H22N4O5): 
1
H NMR (400 MHz, DMSO) : 2.5 (s, 1 H, NH amine), 2.63-2.66 (m, 2 
H, CH2 10’), 2.74-2.77 (m, 2 H, CH2 3’), 3.35-3.38 (m, 2 H, CH2 9’), 3.49-3.55 (m, 6 H, 3xCH2 4’ 6’ 
7’), 4.01 (d, J= 1.9 Hz, 2 H, CH2 1’), 6.76 (br s, 1 H, H3), 7.38-7.42 (m, 1 H, H6), 8.30 (dd, J= 8.1 and 
1.3 Hz, 1 H, H5), 8.40 (dd, J= 8.1 and 1.3 Hz, 1 H, H7), 11.0 (br s, 1 H, NH lactame). 
13
C NMR (150 
MHz, DMSO) : 41.7 (CH2), 48.7 (CH2), 50.0 (CH2), 70.0 (CH2), 70.1 (CH2), 70.6 (CH2), 73.2 (CH2), 
120.4 (CH), 121.4 (C), 121.5 (CH), 127.7 (CH), 132.8 (CH), 133.7 (C), 134.6 (C), 150.7 (C), 161.2 
(C). HRMS (ESI) calcd for C16H23N4O5 [M+H]
+
 351.1668, found 351.1674. 
  
Preparation of 4-bromo-8-nitroquinolin-2(1H)-one 13
17 
Acetonitrile (10 mL) and 500 µL of a 70% perchloric acid solution (5.4 mmol, 6 equiv.) were added 
onto 300 mg of 2,4-dibromo-8-nitroquinoline (0.90 mmol, 1 equiv.) in a sealed tube. The reaction 
mixture was then heated at 100°C in a microwave reactor during 1 h. The reaction mixture was poured 
into ice, neutralized with K2CO3 and extracted three times with dichloromethane. The organic layer 
was washed with water, dried over anhydrous Na2SO4 and evaporated in vacuo. 4-bromo-8-
nitroquinolin-2(1H)-one 13 was isolated and recrystallized in acetonitrile to yield a yellow solid (87%, 
0.78 mmol, 211 mg). 
Compound 13 (C9H5BrN2O3): mp 239 °C (Lit: 240 °C), 
1
H NMR (300 MHz, CDCl3) : 7.20 (d, J= 2.0 
Hz, 1 H, H3), 7.37-7.42 (m, 1 H, H6), 8.36 (dd, J= 8.0 and 1.4 Hz, 1 H, H5), 8.58 (dd, J= 8.3 and 1.4 
Hz, 1 H, H7), 11.42 (br s, 1 H, NH). 
13
C NMR (100 MHz, DMSO) : 121.0 (C), 122.6 (CH), 126.9 
(CH), 129.4 (CH), 132.7 (C), 134.8 (C), 135.5 (CH), 136.5 (C), 159.5 (C). 
 
Preparation of N-methylquinolin-2(1H)-one 16
36 
DMF (30 mL) was added onto 1 g of quinoline-2(1H)-one (6.9 mmol, 1 equiv.), 1.43 g of K2CO3 (10.3 
mmol, 1.5 equiv.). The reaction mixture was heated at 80°C and 430 µL of methane iodide (6.9 mmol, 
1 equiv.) were added dropwise. After 48 h, the reaction mixture was poured into water and extracted 
three times with dichloromethane. The organic layer was washed 5 times with water, dried over 
anhydrous Na2SO4 and evaporated in vacuo. The crude residue was purified by chromatography on 
silica gel using dichloromethane/ethyl acetate (7.5/2.5) as eluent. N-methylquinolin-2(1H)-one 16 was 
isolated and recrystallized in isopropanol to yield a white solid (71%, 4.90 mmol, 780 mg).  
Compound 16 (C10H9NO): mp 76 °C (Lit: 74 °C), 
1
H NMR (400 MHz, CDCl3) : 3.73 (s, 3 H, CH3),  
6.71 (d, J=9.4 Hz, 1 H, H3), 7.21-7.25 (m, 1 H, H6),  7.37 (dd, J= 8.1 and 1.0 Hz, 1 H, H5), 7.55-7.59 
(m, 2 H, H7 - H8), 7.67 (d, J=9.5 Hz, 1 H, H4). 
13
C NMR (100 MHz, CDCl3) : 29.4 (CH3), 114.1 
(CH), 120.6 (C), 121.7 (CH), 122.1 (CH), 128.7 (CH), 130.6 (CH), 138.9 (CH), 140.0 (C), 162.3 (C). 
  
Preparation of 2-methoxy-8-nitroquinoline 21
16 
Under Argon atmosphere, 100 mg of 8-nitroquinolin-2(1H)-one (0.53 mmol, 1 equiv.) were 
solubilized in 5 mL of DMF and were added onto a DMF solution (5 mL) of 42 mg of 60% sodium 
hydride (1.05 mmol, 2 equiv.). After 10 min of stirring at rt, 65 µL of methyl iodide (1.05 mmol, 2 
equiv.) were added dropwise. After one night stirring at rt, the reaction mixture was poured into ice. 
The resulting precipitate was filtered and dried in vacuo. The crude residue was purified by 
chromatography on silica gel using diethyl ether as eluent. 2-methoxy-8-nitroquinoline 21 was isolated 
and recrystallized in cyclohexane to yield a pale white solid (64%, 0.34 mmol, 70 mg).  
Compound 21 (C10H8N2O3): mp 125 °C (Lit: 114 °C), 
1
H NMR (400 MHz, CDCl3) : 4.09 (s, 3 H, 
CH3), 7.05 (d, J= 8.9 Hz, 1 H, H3), 7.42-7.46 (m, 1 H, H6), 7.93 (dd, J= 8.1 and 1.4 Hz, 1 H, H5), 
7.99 (dd, J= 7.6 and 1.4 Hz, 1 H, H7), 8.07 (d, J= 8.9 Hz, 1 H, H4). 
13
C NMR (100 MHz, CDCl3) : 
54.1 (CH3), 115.1 (CH), 122.6 (CH), 124.0 (CH), 126.2 (C), 131.5 (CH), 138.2 (C), 138.5 (CH), 146.6 
(C), 163.7 (C). 
 
Preparation of 3-bromo-8-nitroquinolin-2(1H)-one 22
 
Fifty milliliters of a 48% hydrobromic acid solution were added onto 1.34 g of 8-nitroquinolin-2(1H)-
one (7.05 mmol, 1 equiv.). The reaction mixture was then stirred at 100°C. Then 3.2 g of sodium 
bromate (21.1 mmol, 3 equiv.) were added with precaution (Br2 formation). After 5 h under reflux, the 
reaction mixture was left for 2 h under the hood to evacuate remaining Br2 vapors, and then poured 
into ice, neutralized with K2CO3 and extracted three times with dichloromethane. The organic layer 
was washed with water, dried over anhydrous Na2SO4 and evaporated in vacuo.  
The crude residue was purified by chromatography on silica gel using cyclohexane/ethyl acetate (1/1) 
as an eluent. 3-bromo-8-nitroquinolin-2(1H)-one 22 was isolated and recrystallized in acetonitrile to 
yield a yellow solid (68%, 4.8 mmol, 1.3 g).  
Compound 22 (C9H5BrN2O3): mp 216 °C, 
1
H NMR (400 MHz, CDCl3) : 7.36-7.40 (m, 1 H, H6), 
7.89 (dd, J= 8.4 and 1,4 Hz, 1 H, H5), 8.6 (s, 1 H, H4), 8.56 (dd, J= 7,7 and 1,6 Hz, 1 H, H7), 11.51 
(br s, 1 H, NH). 
13
C NMR (100 MHz, CDCl3) : 119.9 (C), 122.1 (CH), 122.3 (C), 128.0 (CH), 132.9 
(C), 133.2 (C), 134.8 (CH), 141.0 (CH), 157.5 (C). HRMS (DCI CH4) calcd for C9H6BrN2O3 [M+H]
+
 
268.9562, found 268.9554. 
 
Preparation of 3-chloro-8-nitroquinolin-2(1H)-one 23
 
Fifty milliliters of a 37% hydrochloric acid solution were added onto 1 g of 8-nitroquinolin-2(1H)-one 
(5.3 mmol, 1 equiv.). The reaction mixture was then stirred at 100°C before 1.7 g of sodium chlorate 
(15.8 mmol, 3 equiv.) were added with precaution (Cl2 formation). After 45 min under reflux, the 
reaction mixture was left for 2 h under the hood to evacuate remaining Cl2 vapors, and then was 
poured into ice, neutralized with K2CO3 and extracted three times with dichloromethane. The organic 
layer was washed with water, dried over anhydrous Na2SO4 and evaporated in vacuo. The crude 
residue was purified by chromatography on silica gel using diethyl ether as an eluent. 3-chloro-8-
nitroquinolin-2(1H)-one 23 was isolated and recrystallized in acetonitrile to yield a yellow solid (62%, 
3.3 mmol, 738 mg).  
Compound 23 (C9H5ClN2O3): mp 195 °C, 
1
H NMR (400 MHz, CDCl3) : 7.37-7.41 (m, 1 H, H6), 7.88 
(dd, J= 7.7 and 1.4 Hz, 1 H, H5), 8.04 (s, 1 H, H4), 8.55 (dd, J=8.4 and 1.4 Hz, 1 H, H7), 11.56 (br s, 
1 H, NH). 
13
C NMR (100 MHz, CDCl3) : 121.8 (C), 122.2 (CH), 127.9 (CH), 129.2 (C), 132.3 (C), 
133.1 (C), 134.9 (CH), 137.0 (CH), 157.5 (C). HRMS (DCI CH4) calcd for C9H6ClN2O3 [M+H]
+
 
225.0067, found 225.0070. 
 
Preparation of 3-bromo-2-methoxy-8-nitroquinoline 24
 
Under Argon atmosphere, 250 mg of 3-bromo-8-nitroquinolin-2(1H)-one (0.93 mmol, 1 equiv.) were 
solubilized in 5 mL of dry DMF and were added onto a DMF solution (5 mL) of 74 mg of 60% 
sodium hydride (1.86 mmol, 2 equiv.). After 10 min of stirring at rt, 115 µL of methyl iodide (1.86 
mmol, 2 equiv.) were added dropwise. The reaction mixture was stirred at rt overnight, before being 
poured into ice. The resulting precipitate was filtered and dried in vacuo. The crude residue was 
purified by chromatography on silica gel using cyclohexane/acetone (9/1) as eluent. 3-bromo-2-
methoxy-8-nitroquinoline 24 was isolated to yield a pale white solid (55%, 0.51 mmol, 146 mg).  
Compound 24 (C10H7BrN2O3): mp 208 °C, 
1
H NMR (300 MHz, CDCl3) : 4.15 (s, 3 H, CH3), 7.43-
7.49 (m, 1 H, H6), 7.86 (dd, J= 8.1 and 1.4 Hz, 1 H, H5), 8.02 (dd, J= 7.7 and 1.4 Hz, 1 H, H7), 8.35 
(s, 1 H, H4). 
13
C NMR (100 MHz, CDCl3) : 55.4 (CH3), 110.4 (C), 123.5 (CH), 124.4 (CH), 127.1 
(C), 130.6 (CH), 136.7 (C), 140.6 (CH), 146.2 (C), 159.2 (C). HRMS (DCI CH4) calcd for 
C10H7BrN2O3 [M+H]
+
 282.9718, found 282.9722. 
 
Preparation of 8-amino-3-bromoquinolin-2(1H)-one 25
 
Ethanol (20 mL) was added onto 300 mg of 3-bromo-8-nitroquinolin-2(1H)-one (1.11 mmol, 1 equiv.) 
and 1.1 g of tin (II) chloride (5.55 mmol, 5 equiv.). The reaction mixture was refluxed for 3 h. The 
reaction mixture was then neutralized into an aqueous solution of Na2CO3, filtered on celite, extracted 
three times with dichloromethane and once with ethyl acetate. The combined organic layers were 
washed with water, dried over anhydrous Na2SO4 and evaporated in vacuo. The crude residue was 
purified by chromatography on silica gel using dichloromethane/methanol (95/5) as eluent. 8-amino-3-
bromoquinolin-2(1H)-one 25 was isolated to yield a pale brown solid (53%, 0.59 mmol, 140 mg).  
Compound 25 (C9H7BrN2O): Dec. 248 °C, 
1
H NMR (400 MHz, DMSO-d6) : 5.60 (br s, 2 H, NH2), 
6.84 (dd, J= 7.5 and 1.5 Hz, 1 H, H7), 6.90 (dd, J= 7.7 and 1.5 Hz, 1 H, H5), 6.95-6.99 (m, 1 H, H6), 
8.40 (s, 1 H, H4), 11.35 (br s, 1 H, NH). 
13
C NMR (100 MHz, DMSO-d6) : 115.2 (CH), 115.5 (CH), 
116.6 (C), 120.6 (C), 123.5 (CH), 125.6 (C), 135.4 (C), 143.2 (CH), 158.3 (C). HRMS (DCI CH4) 
calcd for C10H7BrN2O3 [M+H]
+
 238.9820, found 238.9820. 
 
General procedure for the preparation of 5-methyl-8-nitroquinolin-2(1H)-one 26, 6-methyl-8-
nitroquinolin-2(1H)-one 27
37
, 7-methyl-8-nitroquinolin-2(1H)-one 28, 5-methoxy-8-nitroquinolin-
2(1H)-one 29, 6-methoxy-8-nitroquinolin-2(1H)-one 30
38
 and 7-methoxy-8-nitroquinolin-2(1H)-one 
31. 
In a first step, according to a previously reported procedure,
21 
1.2 equiv. of 3,3’-diethoxyacryloyl 
chloride (prepared from ethyl 3,3’-diethoxypropionate by successive saponification and reaction with 
SOCl2)
 
was reacted at rt with 1 equiv. of the appropriate nitroaniline derivative in dichloromethane, in 
the presence of 2 equiv. of pyridine. The reaction mixtures were then poured into water and extracted 
three times with dichloromethane. The organic layers were washed with brine, dried over anhydrous 
Na2SO4 and evaporated in vacuo. In a second step, each crude residue was reacted with 98% sulfuric 
acid and stirred at rt for 3-4 h (monitored by TLC). The reaction mixtures were then poured into ice, 
neutralized with K2CO3 and extracted three times with dichloromethane. The organic layers were washed 
with water, dried over anhydrous Na2SO4 and evaporated in vacuo. The final crude residues were 
purified by chromatography on silica gel.  
5-methyl-8-nitroquinolin-2(1H)-one 26 (C10H8N2O3) was purified by chromatography on silica gel using 
cyclohexane/ethyl acetate (90/10) as eluent, isolated and recrystallized in acetonitrile to yield a pale 
brown solid (46%, 2.39 mmol, 490 mg), mp 213 °C, 
1
H NMR  (400 MHz, DMSO-d6) : 2.67 (s, 3 H, 
CH3), 6.78 (dd, J= 10.0 and 2.2 Hz, 1 H, H3), 7.15 (dd, J= 8.5 and 0.6 Hz, 1 H, H6), 7.99 (d, J= 10.0 
Hz, 1 H, H4), 8.40 (d, J= 8.5 Hz, 1 H, H7), 11.5 (br s, 1 H, NH). 
13
C NMR (100 MHz, DMSO-d6) : 
19.8 (CH3), 120.1 (C), 123.1 (CH), 123.3 (CH), 127.8 (CH), 131.7 (C), 134.1 (C) 136.6 (CH), 145.4 
(C), 161.3 (C). HRMS (DCI CH4) calcd for C10H9N2O3 [M+H]
+
 205.0613, found 205.0608. 
 
6-methyl-8-nitroquinolin-2(1H)-one 27 (C10H8N2O3) was purified by chromatography on silica gel 
using cyclohexane/ethyl acetate (90/10) as eluent and isolated to yield a brown solid (6%, 0.34 mmol, 
70 mg), mp 200 °C (Lit: 199-200), 
1
H NMR (400 MHz, CDCl3) : 2.50 (s, 3H, CH3), 6.74 (dd, J=9.7 
and 2.0 Hz, 1 H, H3), 7.69 (s, 1 H, H5), 7.74 (d, J=9.7 Hz, 1 H, H4), 8.33 (d, J=2.0 Hz, 1H, H7), 11.22 
(br s, 1 H, NH). 
13
C NMR (100 MHz, CDCl3) : 20.5 (CH3), 122.0 (C), 123.7 (CH), 128.4 (CH), 131.7 
(C), 131.8 (C), 132.8 (C), 135.9 (CH) 139.7 (CH), 161.6 (C). 
 
7-methyl-8-nitroquinolin-2(1H)-one 28 (C10H8N2O3) was purified by chromatography on silica gel 
using cyclohexane/ethyl acetate (90/10) as eluent, isolated and recrystallized in acetonitrile to yield a 
yellow solid (52%, 3.42 mmol, 700 mg), mp 233 °C, 
1
H NMR (400 MHz, CDCl3) : 2.64 (s, 3 H, 
CH3), 6.69 (d, J= 9.6 Hz, 1 H, H6), 7.15 (dd, J= 8.0 and 0.6 Hz, 1 H, H3), 7.64 (d, J= 8.0 Hz, 1 H, 
H4), 7.74 (d, J= 9.6 Hz, 1 H, H5), 10.12 (br s, 1 H, NH). 
13
C NMR (100 MHz, CDCl3) : 21.2 (CH3), 
119.7 (C), 122.7 (CH), 125.5 (CH), 132.2 (CH), 132.6 (C), 135.6 (C) 137.6 (C), 139.9 (CH), 161.7 
(C). HRMS (DCI CH4) calcd for C10H9N2O3 [M+H]
+
 205.0613, found 205.0615. 
 
5-methoxy-8-nitroquinolin-2(1H)-one 29 (C10H8N2O4) was purified by chromatography on silica gel 
using cyclohexane/ethyl acetate (90/10) as eluent, isolated and recrystallized in acetonitrile to yield a 
dark orange solid (21%, 0.61 mmol, 135 mg), mp 246 °C, 
1
H NMR (400 MHz, CDCl3) : 4.09 (s, 3 H, 
OCH3), 6.68 (dd, J= 10.0 and 2.1 Hz, 1 H, H3), 6.73 (d, J= 9.4 Hz, 1 H, H6), 8.17 (d, J= 9.9 Hz, 1 H, 
H4), 8.52 (d, J= 9.4 Hz, 1 H, H7), 11.45 (br s, 1H, NH).  
13
C NMR (100 MHz, CDCl3) : 56.8 (OCH3), 
102.8 (CH), 110.7 (C), 121.8 (CH), 127.0 (C), 130.6 (CH), 134.6 (CH) 135.6 (C), 161.7 (C), 161.8 
(C). HRMS (DCI CH4) calcd for C10H9N2O3 [M+H]
+
 221.0562, found 221.0561. 
 
6-methoxy-8-nitroquinolin-2(1H)-one 30 (C10H8N2O4) was purified by chromatography on silica gel 
using cyclohexane/ethyl acetate (90/10) as eluent and isolated to yield a pale brown solid (4%, 0.05 
mmol, 12 mg), mp 210 °C (Lit : 210-211 °C), 
1
H NMR (400 MHz, CDCl3) : 3.93 (s, 3 H, OCH3), 
6.76 (dd, J= 9.7 and 1.8 Hz, 1 H, H3), 7.42 (d, J= 2.9 Hz, 1 H, H5), 7.73 (d, J= 9.7 Hz, 1 H, H4), 8.07 
(d, J= 2.9 Hz, 1 H, H7), 11.15 (br s, 1H, NH).  
13
C NMR (100 MHz, CDCl3) : 56.3 (OCH3), 113.5 
(CH), 113.9 (C), 120.7 (CH), 122.9 (C), 124.4 (CH), 128.3 (C) 139.4 (CH), 153.5 (C), 161.4 (C). 
 
7-methoxy-8-nitroquinolin-2(1H)-one 31 (C10H8N2O4) was purified by chromatography on silica gel 
using dichloromethane/ethyl acetate (90/10) as eluent, isolated and recrystallized in acetonitrile to 
yield a yellow solid (45%, 0.79 mmol, 175 mg), mp 244 °C, 
1
H NMR (400 MHz, CDCl3) : 4.04 (s, 3 
H, OCH3), 6.57 (d, J= 9.6 Hz, 1 H, H3), 6.93 (d, J= 8.9 Hz, 1 H, H6), 7.68 (d, J= 9.3 Hz, 2 H, H4 H5), 
9.9 (br s, 1H, NH). 
13
C NMR (100 MHz, CDCl3) : 57.2 (OCH3), 105.0 (C), 106.9 (CH), 114.3 (C), 
120.6 (CH), 133.5 (CH), 133.7 (C) 139.9 (CH), 155.9 (C), 161.8 (C).  HRMS (DCI CH4) calcd for 
C10H9N2O3 [M+H]
+
 221.0562, found 221.0556. 
 
 
Electrochemistry 
Voltammetric measurements were carried out with a potentiostat
 
Autolab PGSTAT100 (ECO Chemie, 
The Netherlands) controlled by GPES 4.09 software. Experiments were performed at room 
temperature in a homemade airtight three–electrode cell connected to a vacuum/argon line. The 
reference electrode consisted of a saturated calomel electrode (SCE) separated from the solution by a 
bridge compartment. The counter electrode was a platinum wire of approximately 1cm² apparent 
surface. The working electrode was GC microdisk (1.0 mm of diameter – Bio-logic SAS). The 
supporting electrolyte (nBu4N)[PF6] (Fluka, 99% puriss electrochemical grade) and the solvent DMSO 
(Sigma-Aldrich puriss p.a. dried<0.02% water) were used as received and simply degassed under 
argon. The solutions used during the electrochemical studies were typically 10
-3
 M in compound and 
0.1 M in supporting electrolyte. Before each measurement, the solutions were degassed by bubbling 
Ar and the working electrode was polished with a polishing machine (Presi P230). Under these 
experimental conditions employed in this work, the half-wave potential (E1/2) of the ferrocene Fc+/Fc 
couple in DMSO was E1/2 = 0.45 V vs SCE. Experimental peak potentials have been measured versus 
SCE and converted to NHE by adding 0.241 V. 
 
Computational studies 
All the calculations were carried out with the GAUSSIAN 09 suite
39
. Geometry optimizations were 
performed with the M06-2x
40
 density functional and the 6-311++G (2d,2p) basis set. Previous studies 
have indicated that extended basis sets, with diffuse s- and p-type functions and polarization functions 
were important for the description of the electronic affinity of nitrobenzene derivatives
22,23
. The effect 
of solvation were described with the self-consistent reaction field (SCRF) method using the integral 
equation formalism polarizable continuum Model (IEFPCM) with DMSO as solvent
41
. Vibrational 
frequency calculation were used to confirm the convergence to local minima and to calculate the 
unscaled zero-point-energy (ZPE) and the entropy corrections at 298 K. The standard variation of the 
Gibb’s free energies were calculated as the energy difference between anion-radical and neutral forms 
after full geometry optimization according to the following equation: R-NO2 + 1 e
- . R-NO2
.-
. 
Reduction potentials of the nitro-compounds were calculated using the equation based on Faraday’s 
law: 
 
    
     
  
   
  (1) where Gred is the Gibbs free energy of reduction, n is the number of 
electrons transferred (i.e. one electron), F is the Faraday constant which equals 23.06 kcal.mol
-1
.V
-1
 
and   
   is the absolute potential of the normal hydrogen electrode. The   
  value was taken as -4.28 V. 
42
 
Biology 
Antileishmanial activity on L. infantum axenic amastigotes.
43
 
L. infantum promastigotes (MHOM/MA/67/ITMAP-263, CNR Leishmania, Montpellier, France, 
expressing luciferase activity) in logarithmic phase cultivated in RPMI 1640 medium supplemented 
with 5% foetal calf serum (FCS), 2 mM L-glutamine and antibiotics (100 U/mL penicillin and 100 
µg/mL streptomycin), were centrifuged at 900 g for 10 min. The supernatant was removed carefully 
and was replaced by the same volume of RPMI 1640 complete medium at pH 5.4 and incubated for 24 
h at 24 °C. The acidified promastigotes were incubated for 24 h at 37 °C in a ventilated flask. 
Promastigotes were then transformed into axenic amastigotes. The effects of the tested compounds on 
the growth of L. infantum axenic amastigotes were assessed as follows. L. infantum amastigotes were 
incubated at a density of 2.10
6
 parasites/mL in sterile 96-well plates with various concentrations of 
compounds dissolved in DMSO (final concentration less than 0.5% v/v), in duplicate. Appropriate 
controls DMSO, amphotericin B, miltefosine and fexinidazole (reference drugs purchased from Sigma 
Aldrich) were added to each set of experiments. After a 48 h incubation period at 37 °C, each plate-
well was then microscope-examined for detecting any precipitate formation. To estimate the luciferase 
activity of axenic amastigotes, 80 µl of each well are transferred to white 96-well plates, Steady 
Glow® reagent (Promega) was added according to manufacturer's instructions, and plates were 
incubated for 2 min. The luminescence was measured in Microbeta Luminescence Counter 
(PerkinElmer). Inhibitory concentration 50% (IC50) was defined as the concentration of drug required 
to inhibit by 50% the metabolic activity of L. infantum amastigotes compared to control. IC50 values 
were calculated by non-linear regression analysis processed on dose response curves, using 
TableCurve 2D V5 software. IC50 values represent the mean of three independent experiments. 
 
Antileishmanial activity on L. donovani promastigotes.  
The effects of the tested compounds on the growth of L. donovani promastigotes 
(MHOM/IN/00/DEVI) were assessed by MTT assay.44 Briefly, promastigotes in logarithmic phase in 
Schneider’s medium supplemented with 20% foetal calf serum (FCS), 2 mM L-glutamine and 
antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin), were incubated at an average density 
of 10
6
 parasites/mL in sterile 96-well plates with various concentrations of compounds dissolved in 
DMSO (final concentration less than 0.5% v/v), in duplicate. Appropriate controls treated by DMSO, 
miltefosine or amphotericin B (reference drugs purchased from Sigma Aldrich) were added to each set 
of experiments. After a 72 h incubation period at 27 °C, parasite metabolic activity was determined. 
Each plate-well was then microscope-examined for detecting possible precipitate formation. 10µL of 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (10 mg/mL in PBS) 
were added to each well followed by incubation for another 4 h. The enzyme reaction was then 
stopped by addition of 100 µL of 50% isopropanol–10% sodium dodecyl sulfate. Plates were shaken 
vigorously (300 rpm) for 10 min. The absorbance was finally measured at 570 nm in a BIO-TEK 
ELx808 Absorbance Microplate Reader. Inhibitory concentration 50% (IC50) was defined as the 
concentration of drug required to inhibit by 50% the metabolic activity of L. donovani and 
promastigotes compared to the control. IC50 were calculated by nonlinear regression analysis 
processed on dose–response curves, using TableCurve 2D V5.0 software. IC50 values represent the 
mean value calculated from three independent experiments. 
 
Antileishmanial activity on L. donovani intracellular amastigotes.  
The effects of the tested compounds on the growth of Leishmania donovani intracellular amastigotes 
(MHOM/IN/00/DEVI) were assessed according to the method of Da Luz et al.45 400 µL of THP-1 
cells activated with Phorbol 12-Myristate 13-Acetate (final concentration: 50 ng/ml) were seeded in 
sterile chamber-slides at an average density of 10
5
 cells/mL and incubated for 48 h at 37 °C and 6% 
CO2. L. donovani promastigotes were centrifuged at 900g for 10 min and the supernatant replaced by 
the same volume of Schneider 20% FCS pH 5.4 and incubated for 24 h at 27 °C. THP-1 cells were 
then infected by acidified promastigotes at an average density of 10
6
 cells/mL (10:1 ratio) and 
chamber-slides incubated for 24 h at 37 °C. Then, in duplicate, the medium containing various 
concentrations of tested-compounds was added (final DMSO concentration being inferior to 0.5% 
v/v). Appropriate controls treated with or without solvent (DMSO), and various concentrations of 
miltefosine and amphotericin B (reference drugs purchased from Sigma Aldrich) were added to each 
set of experiments. After 120 h incubation at 37 °C and 6% CO2, well supernatant was removed. Cells 
were fixed with analytical grade methanol and stained with 10% Giemsa. The percentage of infected 
macrophages in each assay was determined microscopically by counting at least 200 cells in each 
sample. IC50 was defined as the concentration of drug necessary to produce a 50% decrease of infected 
macrophages compared to the control. IC50 were calculated by non-linear regression analysis 
processed on dose–response curves, using TableCurve 2D V5.0 software. IC50 values represent the 
mean value calculated from three independent experiments. 
 
Antileishmanial activity on L. donovani promastigotes NTR1 and NTR2 over-expressing strain. 
Cell lines and culture conditions: The clonal Leishmania donovani cell line LdBOB (derived from 
MHOM/SD/62/1S-CL2D) was grown as promastigotes at 26 °C in modified M199 media, as 
previously described
46
. LdBOB promastigotes overexpressing NTR1 (LinJ.05.0660)
47
 and NTR2 
(LinJ.12.0730)
48 
were grown in the presence of nourseothricin (100 µg ml
−1
). In vitro drug sensitivity 
assays: To examine the effects of test compounds on growth, triplicate promastigote cultures were 
seeded with 5 × 10
4
 parasites ml
-1
. Parasites were grown in 10 ml cultures in the presence of drug for 
72 h, after which 200 μL aliquots of each culture were added to 96-well plates, 50 μM resazurin was 
added to each well and fluorescence (excitation of 528 nm and emission of 590 nm) measured after a 
further 4 h incubation
49
. Data were processed using GRAFIT (version 5.0.4; Erithacus software) and 
fitted to a 2-parameter equation, where the data are corrected for background fluorescence, to obtain 
the effective concentration inhibiting growth by 50% (EC50): m
EC
I
y
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100
. In this equation [I] 
represents inhibitor concentration and m is the slope factor. Experiments were repeated at least two 
times and the data is presented as the mean plus standard deviation. 
 
Antitrypanosomal activity on T. brucei brucei trypomastigotes. 
Assays were performed on Trypanosoma brucei brucei AnTat 1.9 strain (IMTA, Antwerpen, 
Belgium). It was cultured in MEM with Earle’s salts, supplemented according to the protocol of Baltz 
et al.
50
 with the following modifications, 0.5 mM mercaptoethanol (Sigma Aldrich®, France), 1.5 mM 
L-cysteine (Sigma Aldrich®), 0.05 mM bathocuproïne sulfate (Sigma Aldrich®) and 20% heat-
inactivated horse serum (Gibco®, France), at 37°C in an atmosphere of 5% CO2. The parasites were 
incubated at an average density of 2000 parasites/well in sterile 96-wells plates (Mc2®, France) with 
various concentrations of compounds dissolved in DMSO (Sigma Aldrich®), in duplicate. Reference 
drugs suramin, pentamidine, eflornithine, and fexinidazole (purchased from Sigma Aldrich, France 
and Fluorochem, UK) suspended in NaCl 0.9% or DMSO, were added to each set of experiments. The 
effects of the tested compounds were assessed by the viability marker Alamar Blue® (Fisher, France) 
assay described by Räz et al.
51
 After a 69 h incubation period at 37 °C, 10 µL of Alamar Blue
®
 was 
then added to each well, and the plates were incubated for 5h.
52
 The plates were read in a PerkinElmer 
ENSPIRE (Germany) microplate reader using an excitation wavelength of 530 nm and an emission 
wavelength of 590 nm.  IC50 were calculated by nonlinear regression analysis processed on dose-
response curves, using GraphPad Prism software (USA). IC50 was defined as the concentration of drug 
necessary to inhibit by 50% the viability of T. brucei brucei compared to the control. IC50 values were 
calculated from three independent experiments in duplicate. 
 Antitrypanosomal activity on T. b. brucei trypomastigotes NTR1 over-expressing strain. 
Trypanosoma brucei bloodstream-form 'single marker' S427 (T7RPOL TETR NEO) and drug-
resistant cell lines were cultured at 37°C in HMI9-T medium
53
 supplemented with 2.5 μg.mL−1 G418 
to maintain expression of T7 RNA polymerase and the tetracycline repressor protein. Bloodstream 
trypanosomes overexpressing the T. brucei nitroreductase (NTR1)
54 
were grown in medium 
supplemented with 2.5 μg.mL−1 phleomycin and expression of NTR was induced by the addition of 1 
μg.mL−1 tetracycline. Cultures were initiated with 1 × 105 cells.mL−1 and sub-cultured when cell 
densities approached 1–2 (× 106).mL−1. 
In order to examine the effects of inhibitors on the growth of these parasites, triplicate cultures 
containing the inhibitor were seeded at 1 × 10
5
 trypanosomes.mL
-1
. Cells overexpressing NTR were 
induced with tetracycline 48 h prior to EC50 analysis. Cell densities were determined after culture for 
72 h, as previously described
55
. EC50 values were determined using the following two-parameter 
equation by non-linear regression using GraFit:  
m
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where the experimental data were corrected for background cell density and expressed as a percentage 
of the uninhibited control cell density.In this equation [I] represents inhibitor concentration and m is 
the slope factor. 
 
Cytotoxic evaluation on HepG2 cell line.
 
 
The evaluation of the tested molecules cytotoxicity on the HepG2 (hepatocarcinoma cell line from 
ECACC purchased from Sigma-Aldrich, ref 85011430-1VL certificated without mycoplasma) was 
done according to the method of Mosman with slight modifications.
44
 Briefly, cells (5 x 10
4
 cells/mL) 
in 100 µL of complete medium, [Alpha MEM Eagle from PAN BIOTECH supplemented with 10% 
foetal bovine serum, 2 mM L-glutamine and antibiotics (100 U/mL penicillin and 100 µg/mL 
streptomycin)] were seeded into each well of 96-well plates and incubated at 37 °C and 5% CO2. After 
a 24 h incubation, 100 µL of medium with various product concentrations and appropriate controls 
were added and the plates were incubated for 72 h at 37 °C and 5% CO2. Each plate-well was then 
microscope-examined for detecting possible precipitate formation before the medium was aspirated 
from the wells. 100 µL of MTT solution (0.5 mg/mL in Alpha MEM Eagle) were then added to each 
well. Cells were incubated for 2 h at 37 °C and 5% CO2. After this time, the MTT solution was 
removed and DMSO (100 µL) was added to dissolve the resulting formazan crystals. Plates were 
shaken vigorously (300 rpm) for 5 min. The absorbance was measured at 570 nm with a microplate 
spectrophotometer (Eon BioTek). DMSO was used as blank and doxorubicin (purchased from Sigma 
Aldrich) as positive control. CC50 were calculated by non-linear regression analysis processed on 
dosee response curves, using TableCurve 2D V5 software. CC50 values represent the mean value 
calculated from three independent experiments. 
 
Cytotoxic evaluation on THP1 cell line.
  
The evaluation of the tested molecules cytotoxicity on the differenciated THP-1 cell line (acute 
monocytic leukemia cell line purchased from ATCC, ref TIB-202) was performed according to the 
method of Mosman with slight modifications.
44
 Briefly, cells in 100 µL of complete RPMI medium 
with Phorbol 12-Myristate 13-Acetate (final concentration: 50 ng/ml) were incubated at an average 
density of 10
6
 cells/mL and in sterile 96-well plates. After 48 h incubation, 100 µL of medium with 
various product concentrations dissolved in DMSO (final concentration less than 0.5% v/v) were 
added and the plates were incubated for 72 h at 37 °C.  Each plate-well was then microscope-
examined for detecting possible precipitate formation before the medium was aspirated from the wells. 
100 µL of MTT solution (0.5 mg/mL in medium without FCS) were then added to each well. Cells 
were incubated for 2 h at 37 °C. After this time, the MTT solution was removed and DMSO (100 µL) 
was added to dissolve the resulting blue formazan crystals. Plates were shaken vigorously (300 rpm) 
for 10 min. The absorbance was measured at 570 nm with 630 nm as reference wavelength 
spectrophotometer using a BIO-TEK ELx808 Absorbance Microplate Reader. DMSO was used as 
blank and doxorubicin (purchased from Sigma Aldrich) as positive control. Cell viability was 
calculated as percentage of control (cells incubated without compound). The 50% cytotoxic 
concentration was determined from the dose–response curve by using the TableCurve 2D V5.0 
software. 
 
Ames test method 
Mutagenicity test was carried out by using a modified version
56
 of the liquid incubation assay of the 
classical Ames test. S. typhimurium tester strains (TA97a, TA98, TA100 and TA102) were grown 
overnight in a Nutrient Broth n°2 (Oxoid, France). After this period, 5 - 50 mM DMSO solutions of 
the tested drugs were added to 0.1 mL of culture and incubated with 4% S9 mix for 1 h at 37 °C with 
shaking. Each sample was assayed in duplicate. After incubation, 2 mL of molten top agar were mixed 
gently with the pre-incubated solution and poured onto Vogel-Bonner minimal agar plates. After 48 h 
at 37 °C in the dark, the number of spontaneous and drug induced revertants per plate was determined 
for each dose with a laser bacterial colony counter. A product was considered mutagenic when it 
induces a two-fold increase of the number of revertants, compared with the spontaneous frequency 
(negative control). Benzo[a]pyrene was used as a positive control with all Salmonella strains in 
presence of S9 mix. 
 
Comet assay 
The alkaline comet assay was used to detect DNA strand breaks and alkali-labile sites. Trypsinized 
HepG2 cells were embedded in 0.7% low-melting point agarose (Sigma “Low Gelling Temperature”) 
and laid on pre-cut sheets of polyester film (Gelbond® film) to perform minigel deposits as previously 
described
57
. Film were then placed in lysis solution (NaCl 2.5 M, Na2EDTA 0.1 M, Tris 10 mM, 1 % 
Triton X-100, 10 % DMSO pH 10) for 18h at 4 °C. Electrophoresis (with a solution which contained 
0.3 M NaOH, 1 mM Na2EDTA, pH>13) was processed for 24 min in a tank with a power supply 
giving 28 V (resulting in 0.8 V/cm). After electrophoresis, films were immersed 2 x 5 min in PBS for 
neutralization, followed by fixation in 100% ethanol for 1.5h and drying. After staining with SYBR® 
Gold (Life Technologies) at 10 000 X dilution for 20 min, films were observed at 20x magnification 
with an epifluorescence microscope equipped with an automated platform (Nikon NiE) and coupled to 
a camera (DS-Q1Mc) and the software Nikon NiS Element Advanced Research to automatically 
capture images. In these images, for each cell, the level of DNA damage was evaluated using a semi-
automated scoring system, by measurement of the intensity of all tail pixels divided by the total 
intensity of all pixels in head and tail of comet, by means of the software “Lucia comet assay” 
(Laboratory Imaging, Prague Czech Republic). Fifty cells per deposit and four deposits per sample 
were analysed. The median from these 200 values was calculated, and named “% tail DNA”. 
 
Microsomal stability and plasma protein binding assays 
Microsomal stability protocol. 
The tested product and propranolol, used as reference, are incubated in duplicate (reaction volume of  
0.5 mL) with female mouse microsomes (CD-1, 20 mg / ml, BD Gentest™) at 37 °C in a 50 mM 
phosphate buffer, pH 7.4, in the presence of MgCl2 (5 mM), NADP (1 mM), glucose-6-phosphate 
dehydrogenase (0.4 U/mL) and glucose-6-phosphate (5 mM). For the estimation of the intrinsic 
clearance: 50 μL aliquot at 0, 5, 10, 20, 30 and 40 min are collected and the reaction is stopped with 4 
volumes of acetonitrile (ACN) containing the internal standard. After centrifugation at 10000 g, 10 
min, 4 °C, the supernatants are kept at 4 °C for immediate analysis or placed at -80 °C in case of 
postponement of the analysis. Controls (t0 and tfinal) in triplicate are prepared by incubation of the 
internal standard  with microsomes denatured by acetonitrile. The LC-MS used for this study is a 
Waters® Acquity I-Class / Xevo TQD, equipped with a Waters® Acquity BEH C18 column, 50 x 2.1 
mm, 1.7 μm. The mobile phases are (A) ammonium acetate 10 mM and (B) acetonitrile with 0.1% 
formic acid. The injection volume is 1 µL and the flow rate is 600 µL/min. The chromatographic 
analysis, total duration of 4 min, is made with the following gradient: 0 < t < 0.2 min, 2% (B); 0.2 < t 
< 2 min, linear increase to 98% (B); 2 < t < 2.5 min, 98% (B); 2.5 < t < 2.6 min, linear decrease to 2% 
(B); 2.6 < t < 4 min, 2% (B). 8-Bromo-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-
Microsomal stability assay 
a]pyridine is used as internal standard. The quantification of each compound is obtained by converting 
the average of the ratios of the analyte/internal standard surfaces to the percentage of consumed 
product. The ratio of the control at t0 corresponds to 0% of product consumed. The calculation of the 
half-life (t1/2) of each compound in the presence of microsomes is done according to the equation: 
  
 
 
     
 
. Where k is the first-order degradation constant (the slope of the logarithm of compound 
concentration versus incubation time). The intrinsic clearance in vitro (Clint expressed in μL/min/mg) 
is calculated according to the equation: 
      
    
    
            
 . Where dose is the initial concentration of product in the sample, AUC∞ 
is the area under the concentration-time curve extrapolated to infinity and [microsomes] is the 
microsome concentration expressed in mg/μL. 
 
Plasma protein binding procedure. 
The plasma doped with the tested compound is incubated at 37 °C in triplicate in one of the 
compartments of the insert, the other compartment containing a phosphate buffer solution at pH 7.2. 
After stirring for 4 hours at 300 rpm, a 25 μL aliquot of each compartment is taken and diluted; the 
dilution solution is adapted to obtain an identical matrix for all the compartments after dilution. In 
parallel, the reprocessing of a plasma doped but not incubated will allow to evaluate the recovery of 
the study. The LC-MS used for this study is a Waters® Acquity I-Class / Xevo TQD, equipped with a 
Waters® Acquity BEH C18 column, 50 x 2.1 mm, 1.7 μm. The mobile phases are (A) ammonium 
acetate 10 mM and (B) acetonitrile with 0.1% formic acid. The injection volume is 1 µL and the flow 
rate is 600 µL/min. The chromatographic analysis, total duration of 4 min, is made with the following 
gradient: 0 < t < 0.2 min, 2% (B); 0.2 < t < 2 min, linear increase to 98% (B); 2 < t < 2.5 min, 98% 
(B); 2.5 < t < 2.6 min, linear decrease to 2% (B); 2.6 < t < 4 min, 2% (B). Carbamazepine, oxazepam, 
warfarine and diclofenac are used as reference drugs and Propranolol is used as internal standard. The 
unbound fraction (fu) is calculated according to the following formula:    
                  
          
 
     The percentage of recovery is calculated according to the following formula:           
 
                                   
                    
. Where A is the ratio of the area under peak of the studied molecule 
and the area under peak of the internal standard (propranolol 200 nM). V is the volume of solution 
present in the compartments (VPBS = 350 μL and Vplasma = 200 μL). 
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